×

Abstract on Alliqua's Biovance(R) Product to Receive Award at the Fall 2014 Symposium on Advanced Wound Care

LANGHORNE, Pa., Oct. 13, 2014 (GLOBE NEWSWIRE) -- Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company"), today announced that an abstract on Alliqua's Biovance® Human Amniotic Membrane Allograft is to receive an award at the Fall 2014 Symposium on Advanced Wound Care (SAWC) to be held at the Caesars Palace Hotel & Casino in Las Vegas, Nevada on October 16-19.

Each year, abstracts submitted to the Symposium on Advanced Wound Care (SAWC) are reviewed and scored, in one of four categories, by a blind panel of judges who are experts in the field of wound care. One of the abstracts, previously presented at the Spring 2014 SAWC and authored by Dr. Terry Treadwell et al., is to be recognized as the highest scoring abstract in the "Clinical Research" category. An award in recognition of this achievement will be presented to Dr. Treadwell on Friday, October 17.

The abstract, titled "Treatment of Second Degree Burns with Dehydrated, Decellularized Amniotic Membrane vs. a Nanocrystalline Silver Dressing," summarizes the results of a study designed to evaluate the effectiveness of Biovance® for the treatment of patients with superficial second degree burns. Burn patients who were treated with Biovance® as part of the study healed by 1.3 weeks, while patients with comparable wound sizes who were treated with a silver dressing took up to 2.6 weeks to heal.

On Thursday, October 16, the Company will co-sponsor a breakfast symposium with Sorbion® titled "Hydration Response Technology (HRT): Moving Beyond Exudate Management" from 7:30am - 9:00am ET. The symposium will feature a panel of four speakers, Keith Cutting, MN (Buckinghamshire, UK), Terry Treadwell, MD (Montgomery, AL), S. Kwon Lee, MD (Folsom, CA) and Alexander Maassen, PhD (Senden, Germany), who will discuss the potential clinical benefits and cost savings that can be achieved through the use of Sorbion® wound dressings that feature Hydration Response Technology (HRT). Those who are unable to attend the event may view a replay of Alliqua's recent webinar on the subject at https://goto.webcasts.com/viewer/event.jsp?ei=1041157.

In addition to the breakfast symposium, the Company will showcase thirteen posters highlighting the effectiveness of Sorbion's® advanced wound care dressings and Biovance® at Poster Sessions during the event.

About Alliqua BioMedical, Inc.

Alliqua BioMedical is a provider of advanced wound care solutions. Through its sales and distribution network, together with its proprietary products, Alliqua BioMedical provides a suite of technological solutions intended to enhance the wound care practitioner's ability to deal with the challenges of healing both chronic and acute wounds.

Alliqua BioMedical currently markets its line of hydrogel products for wound care under the SilverSeal® and Hydress® brands, as well as the Sorbion sachet S® and Sorbion sana® wound care products, and its TheraBond 3D® advanced dressing which incorporates the TheraBond 3D® Antimicrobial Barrier Systems technology. It also markets the advanced wound care product Biovance®, as part of its licensing agreement with Celgene Cellular Therapeutics.

In addition, Alliqua BioMedical can provide a custom manufacturing solution to partners in the medical device and cosmetics industry, utilizing its proprietary hydrogel technology. Alliqua BioMedical's electron beam production process, located at its 16,000 square foot GMP manufacturing facility in Langhorne, PA, allows Alliqua BioMedical to develop and custom manufacture a wide variety of hydrogels. Alliqua BioMedical's hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical and cosmetic industries.

For additional information, please visit http://www.alliqua.com. To receive future press releases via email, please visit http://ir.stockpr.com/alliqua/email-alerts.

CONTACT: Investor Relations: Westwicke Partners on behalf of Alliqua Biomedical, Inc. Mike Piccinino, CFA +1-443-213-0500 AlliquaBiomedical@westwicke.com

Source:Alliqua, Inc.